This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bostick, P. J. Articles by Hoon, D. S.B. Search for Related Content PubMed PubMed Citation Articles by Bostick, P. J. Articles by Hoon, D. S.B.

Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase–Polymerase Chain Reaction in Early-Stage Melanoma Patients

From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA.

Address reprint requests to Dave S.B. Hoon, PhD, Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404; email hoon{at}jwci.org

PURPOSE: Detection of micrometastases in the regional tumor-draining lymph nodes is critical for accurate staging and prognosis in melanoma patients. We hypothesized that a multiple-mRNA marker (MM) reverse transcriptase–polymerase chain reaction (RT-PCR) assay would improve the detection of occult metastases in the sentinel node (SN), compared with hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC), and that MM expression is predictive of disease relapse.

PATIENTS AND METHODS: Seventy-two consecutive patients with clinical early-stage melanoma underwent sentinel lymphadenectomy (SLND). Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&E staining and IHC, for melanoma metastases. MM expression in the SNs was correlated with H&E and IHC assay results, standard prognostic factors, and disease-free survival.

RESULTS: In 17 patients with H&E- and/or IHC-positive SNs, 16 (94%) expressed two or more mRNAmarkers. Twenty (36%) of 55 patients with histopathologically negative SNs expressed two or more mRNA markers. By multivariate analysis, patients at increased risk of metastases to the SN had thicker lesions (P = .03), were 60 years of age or younger (P < .05), and/or were MM-positive (P < .001). Patients with histopathologically melanoma-free SNs who were MM-positive, compared with those who were positive for one or fewer mRNA markers, were at increased risk of recurrence (P = .02). Patients who were MM-positive with histopathologically proven metastases in the SN were at greatest risk of disease relapse (P = .01).

CONCLUSION: H&E staining and IHC underestimate the true incidence of melanoma metastases. MM expression in the SN more accurately reflects melanoma micrometastases and is also a more powerful predictor of disease relapse than are H&E staining and IHC alone.

Presented in part at the Thirty-Fourth Annual Meeting of the American Society for Clinical Oncology in Los Angeles, CA, May 16-19, 1998.

This article has been cited by other articles:

				S. Mocellin, D. S.B. Hoon, P. Pilati, C. R. Rossi, and D. Nitti Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis J. Clin. Oncol., April 20, 2007; 25(12): 1588 - 1595. [Abstract] [Full Text] [PDF]

				S. L. Chen, D. M. Iddings, R. P. Scheri, and A. J. Bilchik Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications CA Cancer J Clin, September 1, 2006; 56(5): 292 - 309. [Abstract] [Full Text] [PDF]

				C. Mangas, J. M. Hilari, C. Paradelo, J. Rex, M. T. Fernandez-Figueras, M. Fraile, A. Alastrue, and C. Ferrandiz Prognostic Significance of Molecular Staging Study of Sentinel Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase in Melanoma Patients Ann. Surg. Oncol., July 1, 2006; 13(7): 910 - 918. [Abstract] [Full Text] [PDF]

				C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857. [Abstract] [Full Text] [PDF]

				T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma J. Nucl. Med., June 1, 2006; 47(6): 957 - 967. [Abstract] [Full Text] [PDF]

				R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. Clin. Cancer Res., May 1, 2006; 12(9): 2826 - 2833. [Abstract] [Full Text] [PDF]

				J. Vaquerano, W. G. Kraybill, D. L. Driscoll, R. Cheney, and J. M. Kane III American Joint Committee on Cancer Clinical Stage as a Selection Criterion for Sentinel Lymph Node Biopsy in Thin Melanoma Ann. Surg. Oncol., February 1, 2006; 13(2): 198 - 204. [Abstract] [Full Text] [PDF]

				B. G. Molenkamp, R. J.C.L.M. Vuylsteke, P. A.M. van Leeuwen, S. Meijer, W. Vos, P. G.J.T.B. Wijnands, R. J. Scheper, and T. D. de Gruijl Matched Skin and Sentinel Lymph Node Samples of Melanoma Patients Reveal Exclusive Migration of Mature Dendritic Cells Am. J. Pathol., November 1, 2005; 167(5): 1301 - 1307. [Abstract] [Full Text] [PDF]

				A. Romanini, G. Manca, D. Pellegrino, R. Murr, S. Sarti, F. Bianchi, A. AlSharif, C. Orlandini, V. Zucchi, M. Castagna, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome Ann. Onc., November 1, 2005; 16(11): 1832 - 1840. [Abstract] [Full Text] [PDF]

				D. G. Coit In-Transit Recurrence After Sentinel Lymph Node Biopsy in Melanoma: Primum Non Nocere Ann. Surg. Oncol., August 1, 2005; 12(8): 575 - 578. [Full Text] [PDF]

				D Sahni, A Robson, G Orchard, R Szydlo, A V Evans, and R Russell-Jones The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status J. Clin. Pathol., July 1, 2005; 58(7): 715 - 721. [Abstract] [Full Text] [PDF]

				R. L. Ferris, L. Xi, S. Raja, J. L. Hunt, J. Wang, W. E. Gooding, L. Kelly, J. Ching, J. D. Luketich, and T. E. Godfrey Molecular Staging of Cervical Lymph Nodes in Squamous Cell Carcinoma of the Head and Neck Cancer Res., March 15, 2005; 65(6): 2147 - 2156. [Abstract] [Full Text] [PDF]

				T. Mori, J. Kim, T. Yamano, H. Takeuchi, S. Huang, N. Umetani, K. Koyanagi, and D. S.B. Hoon Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells Cancer Res., March 1, 2005; 65(5): 1800 - 1807. [Abstract] [Full Text] [PDF]

				H. N. Abrahamsen, B. Sandahl Sorensen, E. Nexo, S. J. Hamilton-Dutoit, J. Larsen, and T. Steiniche Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA Clin. Cancer Res., February 15, 2005; 11(4): 1425 - 1433. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]

				R. J. C. L. M. Vuylsteke, B. G. Molenkamp, H. A. Gietema, P. A. M. van Leeuwen, P. G. J. T. B. Wijnands, W. Vos, P. J. van Diest, R. J. Scheper, S. Meijer, and T. D. de Gruijl Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma Cancer Res., November 15, 2004; 64(22): 8456 - 8460. [Abstract] [Full Text] [PDF]

				S. Shivers, M. Alsarraj, R. Guiliano, J. Jakub, S. Pendas, and D. Reintgen Molecular Staging of Melanoma Ann. Surg. Oncol., November 1, 2004; 11(11): 953 - 954. [Full Text] [PDF]

				R. Wlodzimierz, P. Rutkowski, Z. I. Nowecki, J. Kulik, A. Nasierowska-Guttmejer, and J. A. Siedlecki Detection of Melanoma Cells in the Lymphatic Drainage after Lymph Node Dissection in Melanoma Patients by Using Two-Marker Reverse Transcriptase-Polymerase Chain Reaction Assay Ann. Surg. Oncol., November 1, 2004; 11(11): 988 - 997. [Abstract] [Full Text] [PDF]

				U. S. Kammula, R. Ghossein, S. Bhattacharya, and D. G. Coit Serial Follow-Up and the Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction--Staged Sentinel Lymph Nodes From Melanoma Patients J. Clin. Oncol., October 1, 2004; 22(19): 3989 - 3996. [Abstract] [Full Text] [PDF]

				H. N. Abrahamsen, E. Nexo, T. Steiniche, S. J. Hamilton-Dutoit, and B. S. Sorensen Quantification of Melanoma mRNA Markers in Sentinel Nodes: Pre-Clinical Evaluation of a Single-Step Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay J. Mol. Diagn., August 1, 2004; 6(3): 253 - 259. [Abstract] [Full Text]

				M. B. Faries, R. J. Bleicher, X. Ye, R. Essner, and D. L. Morton Lymphatic Mapping and Sentinel Lymphadenectomy for Primary and Metastatic Pulmonary Malignant Neoplasms Arch Surg, August 1, 2004; 139(8): 870 - 877. [Abstract] [Full Text] [PDF]

				H. Takeuchi, D. L. Morton, C. Kuo, R. R. Turner, D. Elashoff, R. Elashoff, B. Taback, A. Fujimoto, and D. S.B. Hoon Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients J. Clin. Oncol., July 1, 2004; 22(13): 2671 - 2680. [Abstract] [Full Text] [PDF]

				T. M. Pawlik, M. I. Ross, and J. E. Gershenwald Lymphatic Mapping in the Molecular Era Ann. Surg. Oncol., April 1, 2004; 11(4): 362 - 374. [Full Text] [PDF]

				H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2351 - 2358. [Abstract] [Full Text] [PDF]

				A. Fujimoto, H. Takeuchi, B. Taback, E. C. Hsueh, D. Elashoff, D. L. Morton, and D. S. B. Hoon Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma Cancer Res., March 15, 2004; 64(6): 2245 - 2250. [Abstract] [Full Text] [PDF]

				D. L. Morton Sentinel Node Mapping and an International Sentinel Node Society: Current Issues and Future Directions Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 137S - 143S. [Full Text] [PDF]

				H. Takeuchi, B. Taback, C. Kuo, and D. S. B. Hoon Clinicopathological Utility of Molecular Staging for Melanoma Patients Undergoing Sentinel Lymphadenectomy Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 152S - 155S. [Abstract] [Full Text] [PDF]

				D. S. Reintgen, J. W. Jakub, S. Pendas, G. Swor, R. Giuliano, and S. Shivers The Staging of Malignant Melanoma and the Florida Melanoma Trial Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 186S - 191S. [Abstract] [Full Text] [PDF]

				S. P. L. Leong Paradigm of Metastasis for Melanoma and Breast Cancer Based on the Sentinel Lymph Node Experience Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 192S - 197S. [Abstract] [Full Text] [PDF]

				S. E. Krown and P. B. Chapman Defining Adequate Surgery for Primary Melanoma N. Engl. J. Med., February 19, 2004; 350(8): 823 - 825. [Full Text] [PDF]

				C. T. Kuo, D. S.B. Hoon, H. Takeuchi, R. Turner, H.-J. Wang, D. L. Morton, and B. Taback Prediction of Disease Outcome in Melanoma Patients by Molecular Analysis of Paraffin-Embedded Sentinel Lymph Nodes J. Clin. Oncol., October 1, 2003; 21(19): 3566 - 3572. [Abstract] [Full Text] [PDF]

				A. R. Hess, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix Phosphoinositide 3-Kinase Regulates Membrane Type 1-Matrix Metalloproteinase (MMP) and MMP-2 Activity during Melanoma Cell Vasculogenic Mimicry Cancer Res., August 15, 2003; 63(16): 4757 - 4762. [Abstract] [Full Text] [PDF]

				R. A. Wascher, D. L. Morton, C. Kuo, R. M. Elashoff, H.-J. Wang, M. Gerami, and D. S.B. Hoon Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated With a Melanoma Vaccine J. Clin. Oncol., July 1, 2003; 21(13): 2558 - 2563. [Abstract] [Full Text] [PDF]

				D. Ribuffo, A. Gradilone, M. Vonella, S. Chiummariello, E. Cigna, N. Haliassos, R. Massa, I. Silvestri, S. Calvieri, L. Frati, et al. Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction-Negative Sentinel Nodes in Malignant Melanoma Ann. Surg. Oncol., May 1, 2003; 10(4): 396 - 402. [Abstract] [Full Text] [PDF]

				M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon Epigenetic Inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in Malignant Cutaneous Melanoma Cancer Res., April 1, 2003; 63(7): 1639 - 1643. [Abstract] [Full Text] [PDF]

				S. V. Harden, Y. Tokumaru, W. H. Westra, S. Goodman, S. A. Ahrendt, S. C. Yang, and D. Sidransky Gene Promoter Hypermethylation in Tumors and Lymph Nodes of Stage I Lung Cancer Patients Clin. Cancer Res., April 1, 2003; 9(4): 1370 - 1375. [Abstract] [Full Text] [PDF]

				H. Takeuchi, A. Bilchik, S. Saha, R. Turner, D. Wiese, M. Tanaka, C. Kuo, H.-J. Wang, and D. S. B. Hoon c-MET Expression Level in Primary Colon Cancer: A Predictor of Tumor Invasion and Lymph Node Metastases Clin. Cancer Res., April 1, 2003; 9(4): 1480 - 1488. [Abstract] [Full Text] [PDF]

				A. J. Bilchik, D. T. Nora, L. H. Sobin, R. R. Turner, S. Trocha, D. Krasne, and D. L. Morton Effect of Lymphatic Mapping on the New Tumor-Node-Metastasis Classification for Colorectal Cancer J. Clin. Oncol., February 15, 2003; 21(4): 668 - 672. [Abstract] [Full Text] [PDF]

				V Davids, S H Kidson, and G S Hanekom Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate Mol. Pathol., February 1, 2003; 56(1): 43 - 51. [Abstract] [Full Text] [PDF]

				M. Ayyoub, A. Zippelius, M. J. Pittet, D. Rimoldi, D. Valmori, J.-C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D. E. Speiser Activation of Human Melanoma Reactive CD8+ T Cells by Vaccination with an Immunogenic Peptide Analog Derived from Melan-A/Melanoma Antigen Recognized by T Cells-1 Clin. Cancer Res., February 1, 2003; 9(2): 669 - 677. [Abstract] [Full Text] [PDF]

				H. Takeuchi, C. Kuo, D. L. Morton, H.-J. Wang, and D. S. B. Hoon Expression of Differentiation Melanoma-associated Antigen Genes Is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas Cancer Res., January 15, 2003; 63(2): 441 - 448. [Abstract] [Full Text] [PDF]

				A. Gradilone, P. Gazzaniga, D. Ribuffo, S. Scarpa, E. Cigna, F. Vasaturo, U. Bottoni, D. Innocenzi, S. Calvieri, N. Scuderi, et al. Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients J. Clin. Oncol., January 15, 2003; 21(2): 306 - 312. [Abstract] [Full Text] [PDF]

				B. Taback, K. Hashimoto, C. T. Kuo, A. Chan, A. E. Giuliano, and D. S. B. Hoon Molecular Lymphatic Mapping of the Sentinel Lymph Node Am. J. Pathol., October 1, 2002; 161(4): 1153 - 1161. [Abstract] [Full Text] [PDF]

				S. Raja, T. El-Hefnawy, L. A. Kelly, M. L. Chestney, J. D. Luketich, and T. E. Godfrey Temperature-controlled Primer Limit for Multiplexing of Rapid, Quantitative Reverse Transcription-PCR Assays: Application to Intraoperative Cancer Diagnostics Clin. Chem., August 1, 2002; 48(8): 1329 - 1337. [Abstract] [Full Text] [PDF]

				G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al. Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma* J. Nucl. Med., June 1, 2002; 43(6): 811 - 827. [Abstract] [Full Text] [PDF]

				S. Raja, J. D. Luketich, L. A. Kelly, W. E. Gooding, S. D. Finkelstein, and T. E. Godfrey Rapid, quantitative reverse transcriptase-polymerase chain reaction: Application to intraoperative molecular detection of occult metastases in esophageal cancer J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 475 - 483. [Abstract] [Full Text] [PDF]

				B. Taback, A. D. Chan, C. T. Kuo, P. J. Bostick, H.-J. Wang, A. E. Giuliano, and D. S. B. Hoon Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease Cancer Res., December 1, 2001; 61(24): 8845 - 8850. [Abstract] [Full Text] [PDF]

				T. E. Godfrey, S. Raja, S. D. Finkelstein, W. E. Gooding, L. A. Kelly, and J. D. Luketich Prognostic Value of Quantitative Reverse Transcription-Polymerase Chain Reaction in Lymph Node-negative Esophageal Cancer Patients Clin. Cancer Res., December 1, 2001; 7(12): 4041 - 4048. [Abstract] [Full Text] [PDF]

				R. W. Dubois, S. M. Swetter, M. Atkins, K. McMasters, R. Halbert, S. J. Miller, R. Shiell, and J. Kirkwood Developing Indications for the Use of Sentinel Lymph Node Biopsy and Adjuvant High-Dose Interferon Alfa-2b in Melanoma Arch Dermatol, September 1, 2001; 137(9): 1217 - 1224. [Abstract] [Full Text] [PDF]

				C. M. Balch, A. C. Buzaid, S.-J. Soong, M. B. Atkins, N. Cascinelli, D. G. Coit, I. D. Fleming, J. E. Gershenwald, A. Houghton Jr, J. M. Kirkwood, et al. Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma J. Clin. Oncol., August 15, 2001; 19(16): 3635 - 3648. [Abstract] [Full Text] [PDF]

				B. Taback, Y. Fujiwara, H.-J. Wang, L. J. Foshag, D. L. Morton, and D. S. B. Hoon Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients Cancer Res., August 1, 2001; 61(15): 5723 - 5726. [Abstract] [Full Text] [PDF]

				K.M. Acland, C. Healy, E. Calonje, M. O'Doherty, T. Nunan, C. Page, E. Higgins, and R. Russell-Jones Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Micrometastases of Primary Cutaneous Malignant Melanoma J. Clin. Oncol., May 15, 2001; 19(10): 2674 - 2678. [Abstract] [Full Text] [PDF]

				B. M. Clary, B. Mann, M. S. Brady, J. J. Lewis, and D. G. Coit Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection Ann. Surg. Oncol., April 1, 2001; 8(4): 328 - 337. [Abstract] [Full Text] [PDF]

				G. Palmieri, P. A. Ascierto, A. Cossu, N. Mozzillo, M. L. Motti, S. M.R. Satriano, G. Botti, C. Caraco, E. Celentano, R. A. Satriano, et al. Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay J. Clin. Oncol., March 1, 2001; 19(5): 1437 - 1443. [Abstract] [Full Text] [PDF]

				I. Miyashiro, C. Kuo, K. Huynh, A. Iida, D. Morton, A. Bilchik, A. Giuliano, and D. S.B. Hoon Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes Clin. Chem., March 1, 2001; 47(3): 505 - 512. [Abstract] [Full Text] [PDF]